Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease: A View of the Regulatory Science Qualification Landscape from the Coalition Against Major Diseases CSF Biomarker Team

• Published in: Journal of Alzheimer's disease Vol. 55; no. 1; pp. 19 - 35
• Main Authors: Arnerić, Stephen P., Batrla-Utermann, Richard, Beckett, Laurel, Bittner, Tobias, Blennow, Kaj, Carter, Leslie, Dean, Robert, Engelborghs, Sebastiaan, Genius, Just, Gordon, Mark Forrest, Hitchcock, Janice, Kaplow, June, Luthman, Johan, Meibach, Richard, Raunig, David, Romero, Klaus, Samtani, Mahesh N., Savage, Mary, Shaw, Leslie, Stephenson, Diane, Umek, Robert M., Vanderstichele, Hugo, Willis, Brian, Yule, Susan
• Format: Journal Article
• Language: English
• Published: London, England SAGE Publications 01.01.2017
• Subjects: Alzheimer Disease - cerebrospinal fluid; Biomarkers - cerebrospinal fluid; Clinical Trials as Topic; Drug Approval; Drug Discovery; Humans; cerebrospinal fluid biomarkers; biomarker qualification; Alzheimer’s disease; Coalition Against Major Diseases
• ISSN: 1387-2877; 1875-8908
• DOI: 10.3233/JAD-160573

Abstract Alzheimer’s disease (AD) drug development is burdened with the current requirement to conduct large, lengthy, and costly trials to overcome uncertainty in patient progression and effect size on treatment outcome measures. There is an urgent need for the discovery, development, and implementation of novel, objectively measured biomarkers for AD that would aid selection of the appropriate subpopulation of patients in clinical trials, and presumably, improve the likelihood of successfully evaluating innovative treatment options. Amyloid deposition and tau in the brain, which are most commonly assessed either in cerebrospinal fluid (CSF) or by molecular imaging, are consistently and widely accepted. Nonetheless, a clear gap still exists in the accurate identification of subjects that truly have the hallmarks of AD. The Coalition Against Major Diseases (CAMD), one of 12 consortia of the Critical Path Institute (C-Path), aims to streamline drug development for AD and related dementias by advancing regulatory approved drug development tools for clinical trials through precompetitive data sharing and adoption of consensus clinical data standards. This report focuses on the regulatory process for biomarker qualification, briefly comments on how it contrasts with approval or clearance of companion diagnostics, details the qualifications currently available to the field of AD, and highlights the current challenges facing the landscape of CSF biomarkers qualified as hallmarks of AD. Finally, it recommends actions to accelerate regulatory qualification of CSF biomarkers that would, in turn, improve the efficiency of AD therapeutic development.